Another breakthrough news comes from the healthcare and medical sector. A new Covid-19 vaccine will be released on the market to combat the omicron variant specifically. This new vaccine will be effective against the omicron variant and after trial and research, pharmaceutical companies GlaxoSmithKline and Sanofi have confirmed that this is super effective against the omicron variant of coronavirus.

The pharmaceutical companies try to recapture their lost share in the vaccine market which has been heavily dominated by Pfizer and Moderna.

During the trial-and-error research, this bivalent dose of vaccine i.e consisting of two shots was injected into about 13000 people.

The vaccine turned out to be well tolerated, and safe and showed about 65% efficiency against the symptomatic adults who were given both shots.

On the other hand, for the adults who had already suffered from coronavirus, the vaccine turned out to be 75% effective against the new omicron variant.

Overall the clinical result of 92% of efficiency was obtained by the vaccine against the new variant of Covid-19.

The Executive Vice President of Sanofi, Thomas Triomphe stated that the finding from the beta-based booster of the company makes the company hopeful of getting their vaccine shots approved by the regulators.

Executive Vice President of Sanofi,
journalauto.com

The president of GlaxoSmithKline Vaccines, Roger Connor stated that he is hopeful that the vaccine shots for omicron will be available in the market “later this year” and that the vaccine has all the “potential to make an important contribution to public health” as the coronavirus pandemic heads towards its fateful end.

Big giants of the pharmaceutical industry Sanofi and GlaxoSmithKline had been overshadowed largely by Pfizer and BioNTech in the development of the initial Covid-19 vaccine. Now, they are gaining some much-needed ground. Pharmaceutical companies like Johnson & Johnson, Moderna, Novavax, and Pfizer have also been experimenting with the development of an effective vaccine against the omicron variant but Sanofi and GSK took the lead in announcing their trial-and-error lab results and are hopeful that the regulators will approve their vaccine before any other company to be launched in the market sometime later this year.